FIFederica Inturrisi

Federica Inturrisi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Federica Inturrisi has a total of 181 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Human Papillomavirus Testing Compared With Cytology for Cervical Cancer Screening Among Women Living With HIV in the Dominican Republic

    by Margaret M. Madeleine, Flavia Lantigua, Arismendy Benítez Abreu, Hoisex Gomez, Estefani Sánchez Marte, María Isabel Perez, Felix de Jesus Padilla Torres, Ernestina Hernández, Angélica Mondragón, Kelly Shrader, et al.

    Purpose: Women living with HIV (WWH) face elevated cervical cancer risk, yet evidence supporting primary human papillomavirus (HPV) testing in low-resource settings remains limited. We compared HPV testing with cytology for detection of cervical precancer among WWH in the Dominican Republic to inform national screening strategies. Methods: In this cross-sectional analysis from US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network Trial 302 (Estudio Oportunidad, ClinicalTrials.gov identifier: NCT05556772 ), 575 WWH contributed provider- and self-collected samples for cytology and HPV hierarchical testing. Women with positive results on cytology, provider-collected HPV testing, or self-collected HPV testing were referred for colposcopy and biopsy. Screening test characteristics were evaluated using centrally adjudicated histologic end points. Results: Women with positive results on any screening test had higher HIV viral loads, lower CD4 counts, and were younger than women with screen-negative results. Sensitivity to detect cervical intraepithelial neoplasia grade 3 (CIN3+) by cytology (66.7% [95% CI, 49.2 to 80.5]) was lower than sensitivity of provider-collected results with either 13 high-risk HPV (hrHPV) genotypes (93.9 [95% CI, 78.7 to 98.5]) or 8 hrHPV genotypes (84.8% [95% CI, 68.3 to 98.6]). Self-collected samples had the highest sensitivity (97.0%, 95% CI, 81.3 to 99.6). Cytology missed 33.3% of CIN3+, hrHPV testing of provider-collected samples missed 6.1%-15.2% of CIN3+, and hrHPV testing of self-collected samples missed 3.0% of CIN3+. Conclusion: Among WWH in the Dominican Republic, HPV testing, whether provider- or self-collected, outperformed cytology for detection of CIN3+. Both 13- and 8-genotype hrHPV panels demonstrated high sensitivity but low specificity, resulting in high referral rates to colposcopy. These findings support transitioning to primary HPV-based screening for WWH in the Dominican Republic to increase accuracy in detecting precancer and reduce the cervical cancer burden among WWH.

  • Open Access

    Scaling HPV Self-Sampling in Low-Resource Settings: From Evidence to Sustainable Implementation

    by Federica Inturrisi, Beatriz Serrano, Silvia de Sanjosé

    Profound global inequities in cervical cancer burden persist, with nearly 90% of deaths occurring in low- and middle-income countries (LMICs). High-performance human papillomavirus (HPV) testing is the recommended primary screening method, but its scale-up remains constrained by resource and infrastructure limitations. HPV self-sampling optimizes health system resources by eliminating universal speculum examinations during primary screening, yet a critical implementation gap remains regarding how programs transition from pilot projects to routine national practice. To examine this transition, a literature search was conducted through May 2026, focusing on implementation of cervical screening using vaginal self-sampling and molecular DNA amplification techniques within resource-limited settings. While policy endorsement in LMICs expanded from 10 countries in 2020 to 29 in 2026—with 23 recommending self-sampling for all women—real-world implementation lags significantly, as reflected in an estimated five-year HPV-based screening coverage of only 2% in LMICs in 2022. Selected country case studies illustrate diverse delivery models and varying stages of implementation scale, ranging from localized research projects and regional campaigns to scaled national programs: community health worker home visits increased screening uptake four-fold in Argentina, digital health platforms and electronic registries are supporting national scale-up in Malaysia and Rwanda, and single-day near-point-of-care projects achieved very high follow-up rates in remote Amazonian populations. Beyond these country experiences, the review evaluates key considerations along the clinical care cascade, highlighting the importance of triage and treatment capacity, active tracing strategies to minimize loss to follow-up, and supply chain management. Ultimately, self-sampling serves as a promising equity strategy whose success relies on sustained political, financial, and structural commitment across the full clinical pathway.

  • Open Access

    Challenging the assumption that experience- and training-related factors improve accuracy of cervical cancer screening image interpretation: Evidence from Tanzania

    by Federica Inturrisi, Safina Yuma, Bariki Mchome, Alex Mremi, Prisca Dominic Marandu, Nicola West, Melinda Chelva, Rohini R. Datta, Amber Simpson, Kayode O. Ajenifuja, et al.

    Visual inspection of the cervix with acetic acid (VIA), although recognized as inaccurate, remains widely used for cervical screening in low-resource settings. Training and image review by more experienced providers − such as the smartphone-enhanced VIA (SEVIA) in Tanzania − are assumed to improve VIA performance, but remain untested against a reference standard of disease. Between June and December 2023, 486 VIA providers in Tanzania completed a questionnaire on experience- and training-related factors (years practicing VIA, patient volume, refresher training, SEVIA training) and independently reviewed a set of 50 high-quality cervical images (24,300 total reviews). Image reference diagnosis was defined using HPV status and histology: precancer if HPV-positive and histologically-confirmed CIN3, normal if HPV-negative and normal histology, otherwise indeterminate. For comparability, providers’ image reviews were recategorized into positive (VIA-positive for ablation, LEEP, or suspect cancer) or negative (VIA-negative). In an image-level analysis, we calculated proportion of providers labeling each image as positive and averaged those within subgroups of experience/training and reference diagnosis. Overall, providers (mean VIA experience 3.7 years, weekly VIA exams 12.2) showed moderate sensitivity: on average 60.0% (95% confidence interval 59.2 − 60.7) labeled precancers as positive and 54.4% (53.0 − 55.9) labeled normals as negative. More experienced providers tended to be more specific but less sensitive: for example, an average of 56.5% (55.2–57.9) of providers with ≥5 years of VIA experience labeled precancers as positive vs 61.4% (60.5–62.4) of providers with <5 years’ experience; corresponding proportions for images with normal diagnoses were 36.8% (34.3–39.4) vs 44.5% (42.7–46.3). In this image-based evaluation using a virologic/histologic reference diagnosis, VIA showed moderate sensitivity for detecting cervical precancer, and greater provider experience did not substantially increase overall accuracy. These findings challenge assumptions that experience alone improves VIA diagnostic performance, highlighting the need for objective quality assurance and more accurate screening methods.

  • Open Access

    Prevalence, Genotypes Distribution  and factors  associated with high-risk HPV infection among Female sex workers in Kilimanjaro region: “A community-based cross-sectional study”

    by Gumbo D. Silas, Federica Inturrisi, Innocent Peter, Patricia Swai, Nicola West, Barirki Mchome, Alma Nzunda, Gaudensia Olomi, Prisca Marandu, Leah Mmari, et al.

    Objective : This study aimed to determine the prevalence, genotype distribution and factors associated with High-risk human papillomavirus (Hr-HPV) infection among FSWs in Kilimanjaro region, northern Tanzania.Methods: A community-based cross-sectional study was conducted between June and November 2024 among 328 FSWs aged 25–49years. Participants were recruited using respondent-driven sampling(RDS) technique. Vaginal samples were self-collected and tested using the Screen-Fire HPV assay; a rapid, point-of-care molecular test that detects 13 Hr-HPV genotypes grouped into four channels in order of decreasing carcinogenic risk: HPV16; HPV18/45; HPV31/33/35/52/58; HPV39/51/56/59/68). Data were analysed using IBM SPSS Version 27.0. The Modified Poisson regression model was performed. Variables with p-values <0.05 in multivariate analysis, were considered statistically significant.Results: From a total of 328 eligible participants enrolled, the response rate was 309(94%), with a median age of 35 years (IQR: 32–39). The overall prevalence of Hr-HPV was 57.6% (95% CI: 52.1–63.1). The most frequently detected genotypes were HPV31/33/35/52/58 124(40%), followed by HPV39/51/56/59/68 74(24%), HPV16, 53(17%), and HPV18/45 30(10%). Mixed infections 28(9%). Being a Peasant-FSW(APR; 1.28; 95% CI: 1.15–1.45), Housewife-FSW(APR: 1.26; 95% CI: 1.04–1.53), HIV-positive(APR: 1.27; 95% CI: 1.12–1.43), Tobacco smoking(APR: 1.15; 95% CI: 1.04–1.28) and ever screened(APR: 0.83; 95% CI: 0.73–0.94) were significantly associated with Hr-HPV infection. Conclusion: This study highlights the urgent need for targeted cervical cancer prevention strategies among this population. However, further research is also warranted to evaluate the burden of cervical precancer or cancer among this high-risk group to better guide the strategies.

  • Open Access

    Supplementary Table 1 and Supplementary Figure 1 from Sociodemographic Characteristics and Screening Outcomes of Women Preferring Self-Sampling in the Dutch Cervical Cancer Screening Programme: A Population-Based Study

    by Clare A. Aitken, Federica Inturrisi, Sylvia Kaljouw, Daan Nieboer, Albert G. Siebers, Willem J.G. Melchers, Adriaan J.C. van Den Brule, Anco Molijn, John W.J. Hinrichs, Hubert G.M. Niesters, et al.

    Supplementary Table 1: Birthyears invited for screening in 2017 and 2018. Supplementary Figure 1: Data linkage flowchart, describing how CBS data was linked to PALGA data on an individual level

  • Open Access

    Data from Sociodemographic Characteristics and Screening Outcomes of Women Preferring Self-Sampling in the Dutch Cervical Cancer Screening Programme: A Population-Based Study

    by Clare A. Aitken, Federica Inturrisi, Sylvia Kaljouw, Daan Nieboer, Albert G. Siebers, Willem J.G. Melchers, Adriaan J.C. van Den Brule, Anco Molijn, John W.J. Hinrichs, Hubert G.M. Niesters, et al.

    Background:In the Netherlands, lower high-risk human papillomavirus (hrHPV) positivity but higher cervical intraepithelial neoplasia (CIN) 2+ detection were found in self-collected compared with clinician-collected samples. To investigate the possible reason for these differences, we compared sociodemographic and screening characteristics of women and related these to screening outcomes.Methods:We extracted data from PALGA on all primary hrHPV screens and associated follow-up tests for 857,866 screened women, invited in 2017 and 2018. We linked these data with sociodemographic data from Statistics Netherlands. Logistic regression was performed for hrHPV positivity and CIN 2+/3+ detection.Results:Out of the 857,866 women, 6.8% chose to use a self-sampling device. A higher proportion of self-sampling users was ages 30 to 35 years, was not previously screened, was living in a one-person household, or was the breadwinner in the household. After adjustment for these factors self-sampling had lower hrHPV positivity (aOR, 0.65; 95% CI, 0.63–0.68)) as compared with clinician-collected sampling, as well as lower odds of CIN 2+ (aOR, 0.76; 95% CI, 0.70–0.82) and CIN 3+ (aOR, 0.86; 95% CI, 0.78–0.95) detection.Conclusions:It is likely that the observed differences between the two sampling methods are not only related to sociodemographic differences, but related to differences in screening test accuracy and/or background risk.Impact:Self-sampling can be used for targeting underscreened women, as a more convenient screening tool. Further investigation is required to evaluate how to implement self-sampling, when it is used as a primary instrument in routine screening.See related commentary by Arbyn et al., p. 159

  • Open Access

    Prevalence, Genotype Distribution, and Determinants of High-Risk Carcinogenic Human Papillomavirus Infection Among Female Sex Workers in Kilimanjaro Region: A Community-Based Cross-Sectional Study

    by Gumbo D. Silas, Federica Inturrisi, Innocent H. Uggh, Patricia S Swai, Karen Yeates, Nicola West, Bariki Mchome, Alma R. Nzunda, Gaudensia A. Olomi, Prisca D. Marandu, et al.

    Background: High-risk carcinogenic human papillomavirus (hrHPV) is the leading cause of cervical cancer globally. Female sex workers (FSWs) are particularly vulnerable due to high-risk sexual behaviors and low cervical cancer screening uptake. Despite their elevated risk, the prevalence, genotype distribution, and determinants of hrHPV infection among this population in Tanzania remain unknown. Hence this study. Methods: A community-based cross-sectional study was conducted in Kilimanjaro region between June and July 2024, among 309 FSWs aged 25–49 years with no history of precancerous lesions or total hysterectomy. The Respondent-Driven Sampling (RDS) technique was used to recruit this hard-to-reach population. Self-collected vaginal samples were tested using the ScreenFire HPV assay, detecting 13 genotypes grouped into four risk channels. Data were analysed using SPSS Version 27.0, and a modified Poisson regression with robust error variance was applied to estimate associations between predictor variables and hrHPV infection. Statistical significance was set at p < 0.05. Results: Among the 309 FSWs, the mean age was 36.1 years (SD = 5.243), with nearly half (48.5%) aged 25–34 years. The overall hrHPV prevalence was 57.6%, with higher rates among FSWs aged 40–44 years (58.5%), HIV-positive individuals (90.0%), tobacco smokers (76.8%), and those with prior cervical cancer screening (76.5%). Channel-specific hrHPV prevalence was highest for HPV31/33/35/52/58 (23.3%), followed by HPV39/51/56/59/68 (13.6%), HPV16 (9.7%), and HPV18/45 (5.5%). Mixed infections accounted for 5.5%. Religion (APR: 1.45, 95% CI: 1.13–1.61), occupation (APR: 1.28, 95% CI: 1.15–1.45), HIV status (APR: 1.27, 95% CI: 1.12–1.43), tobacco smoking (APR: 1.15, 95% CI: 1.04–1.28), and cervical cancer screening history (APR: 0.83, 95% CI: 0.73–0.94) were significantly associated with hrHPV infection in this population. Conclusion: This study reveals a high prevalence of hrHPV among FSWs in Kilimanjaro, Tanzania, highlighting the urgent need for targeted cervical cancer prevention interventions for this population.

  • Initial evaluation of a new cervical screening strategy combining human papillomavirus genotyping and automated visual evaluation: the Human Papillomavirus–Automated Visual Evaluation Consortium

    by Brian Befano, Jayashree Kalpathy-Cramer, Didem Egemen, Federica Inturrisi, José Jeronimo, Ana Cecilia Rodríguez, Nicole Campos, Miriam Cremer, Ana Ribeiro, Kayode Olusegun Ajenifuja, et al.

    The HPV-Automated Visual Evaluation Consortium is validating a cervical screening strategy enabling accurate cervical screening in resource-limited settings. A rapid, low-cost human papillomavirus (HPV) assay permits sensitive HPV testing of self-collected vaginal specimens; HPV-negative women are reassured. Triage of positive participants combines HPV genotyping (4 groups in order of cancer risk) and visual inspection assisted by automated cervical visual evaluation that classifies cervical appearance as severe, indeterminate, or normal. Together, the combination predicts which women have precancer, permitting targeted management to those most needing treatment. We analyzed CIN3+ yield for each HPV-Automated Visual Evaluation risk level (HPV genotype crossed by automated cervical visual evaluation classification) from 9 clinical sites (Brazil, Cambodia, Dominican Republic, El Salvador, Eswatini, Honduras, Malawi, Nigeria, and Tanzania). Data from 1832 HPV-positive participants confirmed that HPV genotype and automated cervical visual evaluation classification strongly and independently predict risk of histologic CIN3+. The combination of these low-cost tests provided excellent risk stratification, warranting pre-implementation demonstration projects.


  • Open Access

    Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settings

    by Kanan T. Desai, Kayode O. Ajenifuja, Clement A. Adepiti, Federica Inturrisi, Casey Dagnall, Amanda C. Hoffman, Didem Egemen, Julia C. Gage, Nicolas Wentzensen, Silvia de Sanjose, et al.

    Human papillomavirus (HPV) genotype predicts cervical cancer risk, and genotyping could help guide the management of HPV positives as part of cervical screening. An isothermal amplification HPV extended genotyping test (ScreenFire HPV RS assay) can assay up to 96 samples/controls in 1 hour plus preparation time. A novel format with pre-aliquoted reagents and an anti-contamination component (Zebra BioDome) could simplify the HPV testing process and reduce the chances of post-amplification contamination. We validated the Zebra BioDome formulation prior to its clinical use. Residual provider-collected cervical samples ( n = 450) from a population-based study in rural Nigeria were retested with ScreenFire, once using the standard assay version (liquid reagents combined onsite) and twice with Zebra BioDome. HPV results with adequate DNA ( N = 427) were analyzed channel-by-channel and using the cervical cancer risk-based hierarchy of HPV type channels (HPV16, else 18/45, else 31/33/35/52/58, else 39/51/56/59/68, else high-risk HPV negative) to evaluate Zebra BioDome repeatability and accuracy against the standard version. Zebra BioDome reduced the number of pipetting steps to run the ScreenFire HPV assay. Following amplification, the BioDome material formed a sealant layer above the reaction components. Zebra BioDome had excellent repeatability and agreement with the standard version, both at the channel-specific analysis (positive percent agreement between 88.4% [HPV39/51/56/59/68] and 100% [HPV16]; negative percent agreement between 97.8% [HPV31/33/35/52/58] and 100% [HPV39/51/56/59/68]) and hierarchical analysis (overall agreement 97.2%). The assay version utilizing Zebra BioDome performed similarly to the previously validated standard version of the ScreenFire HPV assay and is now undergoing field evaluation. This solution has the potential to reduce assay preparation time and risk of contamination, providing a simpler, low-cost, near-point-of-care HPV testing and extended genotyping solution for cervical screening in lower-resource settings. The potential application of Zebra BioDome technology to other PCR assays should be considered. IMPORTANCE: This work validates a novel pre-packed formulation for the ScreenFire human papillomavirus (HPV) assay, which has the potential to simplify the HPV testing process and to reduce the chances of post-amplification contamination, providing a simpler, low-cost, near-point-of-care HPV testing, and extended genotyping solution for cervical screening in resource-limited settings as part of the ultimate public health goal to accelerate cervical cancer prevention. This technology can also have broad applications for other DNA amplification assays beyond HPV.


  • Open Access

    Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settings

    by Kanan T. Desai, Kayode O. Ajenifuja, Clement A. Adepiti, Federica Inturrisi, Casey L Dagnall, Amanda C. Hoffman, Didem Egemen, Julia C. Gage, Nicolas Wentzensen, Silvia de Sanjose, et al.

    Introduction: Human papillomavirus (HPV) genotype predicts cervical cancer risk, and genotyping could help guide management of HPV positives as part of cervical screening. An isothermal amplification HPV extended genotyping test (ScreenFire HPV RS assay) can assay up to 96 controls/samples in one hour plus preparation time. A novel format with pre-aliquoted reagents and an anti-contamination component (Zebra BioDome™) could simplify the HPV testing process by substantially reducing the assay preparation time and the chances of post-amplification contamination. We validated Zebra BioDome formulation prior to its clinical use. Methods: Residual provider-collected cervical samples (n=450) from a population-based study in rural Nigeria were retested with ScreenFire, once using the standard assay version (liquid reagents combined onsite) and twice with Zebra BioDome. HPV results with adequate DNA (N=427) were analyzed channel-by-channel and using the cervical cancer risk-based hierarchy of HPV type channels (HPV16, else 18/45, else 31/33/35/52/58, else 39/51/56/59/68, else high-risk HPV negative) to evaluate Zebra BioDome repeatability and accuracy against the standard version. Results: Zebra BioDome reduced the number of pipetting steps to run the ScreenFire HPV assay. Following amplification, the BioDome material formed a sealant layer above the reaction components. Zebra BioDome had excellent repeatability and agreement with the standard version, both at the channel-specific analysis [positive percent agreement between 88.4% (HPV39/51/56/59/68) and 100% (HPV16); negative percent agreement between 97.8% (HPV31/33/35/52/58) and 100% (HPV39/51/56/59/68)] and hierarchical analysis (overall agreement 97.2%). Conclusions: The assay version utilizing Zebra BioDome performed similarly to the previously validated standard version of the ScreenFire HPV assay and is now undergoing field evaluation. This solution has the potential to reduce assay preparation time and risk of contamination, providing a simpler, low-cost, near-point-of-care HPV testing and extended genotyping solution for cervical screening in lower-resource settings. Potential application of Zebra BioDome technology to other DNA amplification assays should be considered.